TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33411115

Group type: EXPERIMENTAL
Intervention: Intensive treatment with epoetin beta pegol targeting hemoglobin level of 11 g/dL or higher
Number of subjects: 362

Group type: COMPARATOR
Intervention: Conservative treatment maintaining hemoglobin levels at enrollment (within ± 1 g/dL)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 362
Study: 32407710

Group type: EXPERIMENTAL
Intervention: Lactoferrin supplementation (200 mg/kg once daily)
Number of subjects: 1542

Group type: COMPARATOR
Intervention: No lactoferrin supplement (control group)
Number of subjects: 1542

Group type: EXPERIMENTAL
Intervention: Lactoferrin supplementation (meta-analysis)
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Control group (meta-analysis)
Number of subjects: 1542
Study: 34358324

Group type: EXPERIMENTAL
Intervention: ON-SXB 9 g
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 33783237

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 35175011

Group type: EXPERIMENTAL
Intervention: In-office bleaching (Whiteness HP Maxx) for three sessions of 45 min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: In-office bleaching with PNF desensitizing gel (Desensibilize KF 2%) applied for 10 min before each session
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: In-office bleaching with N desensitizing paste (Desensibilize Nano P) applied after bleaching for 5 min
Number of subjects: 75
Study: 34088270

Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia (fentanyl boluses of 1.0 µg/kg to maintain SPI value between 20 and 50)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional analgesia techniques (fentanyl boluses of 1.0 µg/kg administered when HR or MAP increased to 20% above baseline or HR > 90 bpm)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional analgesia techniques
Number of subjects: 62
Study: 36501157

Group type: EXPERIMENTAL
Intervention: Culturally sensitive diabetes education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard education on COVID-19
Number of subjects: 0
Study: 33626417

Group type: EXPERIMENTAL
Intervention: Pooled samples from batches of slaughter pigs processed twice by two individual samplers.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sampling of single pigs in 30 randomly selected pig pens within the farms.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aggregating the resistance abundance at gene family or antimicrobial class level.
Number of subjects: 30
Study: 32320024

Group type: EXPERIMENTAL
Intervention: Moderate-dose fiber (7 g/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-dose fiber (3 g/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 35399811

Group type: EXPERIMENTAL
Intervention: Ethiodized poppyseed oil-based contrast medium
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Water-based contrast medium
Number of subjects: 1026
Study: 32779606

Group type: EXPERIMENTAL
Intervention: γ‐PGA/TCP
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: γ‐PGA
Number of subjects: 5

Group type: COMPARATOR
Intervention: α‐TCP
Number of subjects: 5

Group type: COMPARATOR
Intervention: CPP‐ACP
Number of subjects: 5

Group type: COMPARATOR
Intervention: deionized water
Number of subjects: 5
Study: 34524022

Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart (FiAsp)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 16
Study: 32105625

Group type: EXPERIMENTAL
Intervention: Point-of-care viral load testing with task shifting to enrolled nurses
Number of subjects: 390

Group type: COMPARATOR
Intervention: Laboratory viral load testing (standard-of-care group)
Number of subjects: 390
Study: 36010630

Group type: EXPERIMENTAL
Intervention: PEA‐LUT therapy
Number of subjects: 69
Study: 34532268

Group type: EXPERIMENTAL
Intervention: Curcumin + BSM (tamsulosin 0.2 mg, finasteride 5 mg, curcumin 2,250 mg once a day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: BSM (tamsulosin 0.2 mg, finasteride 5 mg, placebo)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Curcumin + BSM
Number of subjects: 122
Study: 36315189

Group type: EXPERIMENTAL
Intervention: Automated insulin dosing (AID)
Number of subjects: 120
Study: 33433644

Group type: EXPERIMENTAL
Intervention: 35 mg ASP8062
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 70 mg ASP8062
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paroxetine 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33126854

Group type: EXPERIMENTAL
Intervention: Transport to acute care centre
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Transport to geriatric ward
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Transport to emergency department
Number of subjects: 98
Study: 35367385

Group type: COMPARATOR
Intervention: ONLINE‐ONLY (digital CBT‐I program)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: STEPPED‐CARE (triaged approach with Decision Checklist)
Number of subjects: 240
Study: 34199155

Group type: EXPERIMENTAL
Intervention: Australian method
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Neurac method
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Manual therapy techniques with stabilization techniques
Number of subjects: 69
Study: 34965816

Group type: EXPERIMENTAL
Intervention: Participation in a hypothetical RCT regardless of screening test result
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Randomization to either an intervention or control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reasons to participate in the RCT
Number of subjects: 100
Study: 34699549

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Heparin ± GPIs
Number of subjects: 83
Study: 34839672

Group type: EXPERIMENTAL
Intervention: Immunonutrient-enriched supplement for 7 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard high-protein normocaloric supplement (control) for 7 days
Number of subjects: 43
Study: 32663638

Group type: EXPERIMENTAL
Intervention: Nursing home admission eligibility granted
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nursing home admission eligibility not granted
Number of subjects: 0
Study: 36114953

Group type: EXPERIMENTAL
Intervention: SMR neurofeedback
Number of subjects: 37
Study: 35496724

Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic treatment including spinal manipulation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic treatment including spinal manipulation, together with podiatric custom-made orthoses
Number of subjects: 132
Study: 35732382

Group type: EXPERIMENTAL
Intervention: Structured psychiatric interviews and self‐rated symptom severity scales
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Self‐rated Stress‐Induced Exhaustion Disorder (SED) Instrument (s‐ED)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Montgomery‐Asberg Depression Rating Scale‐self‐rating version and the Karolinska Exhaustion Disorder Scale
Number of subjects: 480
Study: 35860019

Group type: EXPERIMENTAL
Intervention: 10,000 IU/day of cholecalciferol for 14 days
Number of subjects: 85

Group type: COMPARATOR
Intervention: 2,000 IU/day of cholecalciferol for 14 days
Number of subjects: 85
Study: 34148764

Group type: EXPERIMENTAL
Intervention: Prevention program (curriculum)
Number of subjects: 255
Study: 32087126

Group type: EXPERIMENTAL
Intervention: Emollient group (Diprobase cream or DoubleBase gel) with standard skin-care advice
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Control group (standard skin-care advice only)
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Emollient group
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1394
Study: 35316819

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection into the right splenius capitis muscle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection
Number of subjects: 40
Study: 34610257

Group type: EXPERIMENTAL
Intervention: BAK-containing latanoprost (Xalatan)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Preservative-free bimatoprost (Lumigan PF)
Number of subjects: 150
Study: 32297946

Group type: EXPERIMENTAL
Intervention: Smartphone-enabled health monitoring devices (4 devices: weight scale, BP monitor, rhythm monitor, step counter) with 2 electronic visits replacing in-person visits.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Smartphone-enabled health monitoring devices
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regular care (4 physical outpatient clinic visits scheduled in the year following the initial event).
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 200
Study: 34547217

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A therapy (BoNT‐A) with intensive rehabilitation
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 32321717

Group type: EXPERIMENTAL
Intervention: Taxane treatment (docetaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Taxane-sensitive cell lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel treatment
Number of subjects: 0
Study: 33779376

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Yohimbine and Hydrocortisone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 34915104

Group type: EXPERIMENTAL
Intervention: Prebiotic (16 g inulin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus paracasei subsp. paracasei 431)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Synbiotic (combination of prebiotic and probiotic)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (16 g maltodextrin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Synbiotic (21 days consumption)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (21 days consumption)
Number of subjects: 16
Study: 33497643

Group type: EXPERIMENTAL
Intervention: CEH-EUS
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional EUS
Number of subjects: 240
Study: 35783144

Group type: EXPERIMENTAL
Intervention: Tai Chi Quan (60-min classes, three times per week for 12 weeks)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Physical therapy (10 min of evaluation and warm-up, 40 min of therapist-directed exercise therapy, and 10 min of relaxation, three times per week for 12 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Tai Chi Quan
Number of subjects: 138

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 138
Study: 33443588

Group type: EXPERIMENTAL
Intervention: Nipple shield use in pain group (PG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nipple shield use in comparison group (CG)
Number of subjects: 48
Study: 34325499

Group type: EXPERIMENTAL
Intervention: Minimally invasive surfactant therapy (MIST)
Number of subjects: 112

Group type: COMPARATOR
Intervention: INSURE technique
Number of subjects: 112
Study: 33340113

Group type: EXPERIMENTAL
Intervention: Proposed method with contextualized word embedding and multilayer perceptron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stanford NER tagger
Number of subjects: 0
Study: 33802268

Group type: EXPERIMENTAL
Intervention: 2-day bathing cycle
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 4-day bathing cycle
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 32
Study: 33175490

Group type: EXPERIMENTAL
Intervention: Deep learning model based on crystal graph convolutional neural networks for predicting methane adsorption properties.
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Hierarchical screening of hypothetical MOFs database.
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Calculated maximum working capacity of hypothetical MOF.
Number of subjects: 11000
Study: 34711060

Group type: EXPERIMENTAL
Intervention: Jet injection with a slot-shaped nozzle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lancet prick
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Jet injection with differently shaped nozzles
Number of subjects: 20
Study: 32611274

Group type: EXPERIMENTAL
Intervention: Exposed K-wire fixation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Buried K-wire fixation
Number of subjects: 220
Study: 36098249

Group type: EXPERIMENTAL
Intervention: Non-tailored communication (messaging based on CDC's seasonal influenza vaccination campaign)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored communication (comprehensive communication including reinforcement of the importance of influenza vaccination for high-risk individuals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey results (unvaccinated respondents)
Number of subjects: 0
Study: 32738891

Group type: EXPERIMENTAL
Intervention: Inhalational anesthesia (group I): Induced with propofol (1-2 mg/kg) and rocuronium (0.6-1 mg/kg), maintained with 1-2 vol% sevoflurane, 0.01-0.2 μg/kg/min remifentanil, and O2/air (FiO2 0.4).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA) (group T): Induced with propofol (3-6 μg/mL), remifentanil (2-6 ng/mL), and rocuronium (0.6-1 mg/kg) using target controlled infusion (TCI).
Number of subjects: 0
Study: 35833889

Group type: EXPERIMENTAL
Intervention: Germinated brown rice (GBR), 100 g per day for 12 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (regular diet)
Number of subjects: 99
Study: 34480127

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 32513125

Group type: EXPERIMENTAL
Intervention: Slit‐scanning topography (SST)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ultrasonic pachymetry (UP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Optical coherence tomography (OCT)
Number of subjects: 96
Study: 36266474

Group type: EXPERIMENTAL
Intervention: Light/Darkness Cycle (LDC) - light from 07:00 to 19:00 and darkness (25 lx) from 19:00 to 07:00
Number of subjects: 294

Group type: COMPARATOR
Intervention: Continuous Bright Light (CBL) - normal room light conditions 24 hours a day
Number of subjects: 294
Study: 34061695

Group type: EXPERIMENTAL
Intervention: Integrated stress inoculation training (SIT) and exercise
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 53
Study: 32648022

Group type: COMPARATOR
Intervention: 600 mg NZBC extract prior to a high-carbohydrate, high-fat liquid meal (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 8-days supplementation with NZBC extract (600 mg day-1) (n=13)
Number of subjects: 25
Study: 32666739

Group type: EXPERIMENTAL
Intervention: Tomofix plate (locking steel plate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No bone graft
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous bone graft
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic bone graft (fragmented cancellous or wedge-shaped cancellous bone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium-phosphorus bone substitute material
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augment factors
Number of subjects: 0
Study: 33399381

Group type: EXPERIMENTAL
Intervention: Reference listed ropivacaine (NaropinTM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Generic preparation of ropivacaine
Number of subjects: 18
Study: 32318864

Group type: EXPERIMENTAL
Intervention: Pseudomonas strains (6 selected strains)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pseudomonas acidovorans 2R
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All Pseudomonas strains
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa 98.5 and Pseudomonas fluorescens 97.4
Number of subjects: 17
Study: 34240572

Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil (AI) single dose of 480 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil (AI) multiple doses of 480 mg once daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34420828

Group type: EXPERIMENTAL
Intervention: Nurse home visiting
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1138
Study: 35836287

Group type: EXPERIMENTAL
Intervention: Public health nursing interventions plus m-Health applications
Number of subjects: 120

Group type: COMPARATOR
Intervention: m-Health applications alone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 120
Study: 35667771

Group type: EXPERIMENTAL
Intervention: dual‐tDCS with anodal over the lesioned hemisphere M1 and cathodal over the nonlesioned hemisphere, at 2 mA for 20 min before training for five consecutive days
Number of subjects: 25

Group type: COMPARATOR
Intervention: sham tDCS before training
Number of subjects: 25
Study: 35406139

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (15 mg/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (5 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 34245349

Group type: EXPERIMENTAL
Intervention: Ashtanga-Yoga three times a week for 3 months
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ashtanga-Yoga
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 83
Study: 32606635

Group type: EXPERIMENTAL
Intervention: R0.2% ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: R0.3% ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: R0.4% ropivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group without PECS II Block
Number of subjects: 120
Study: 34203286

Group type: EXPERIMENTAL
Intervention: Combined Creatine and Sodium Bicarbonate (CSB) supplementation (20 g/day creatine and 0.3 g/kg/day sodium bicarbonate, taken four times a day for seven days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined Creatine and Sodium Bicarbonate (CSB) supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study: 32375847

Group type: EXPERIMENTAL
Intervention: Emsold metatarsal dome positioned 5 mm proximal to the metatarsal heads
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Langer PPT metatarsal pad positioned 5 mm proximal to the metatarsal heads
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no pad) condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Emsold metatarsal dome positioned in-line with the metatarsal heads
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Emsold metatarsal dome positioned 5 mm distal to the metatarsal heads
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Langer PPT metatarsal pad positioned in-line with the metatarsal heads
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Langer PPT metatarsal pad positioned 5 mm distal to the metatarsal heads
Number of subjects: 36
Study: 32627231

Group type: EXPERIMENTAL
Intervention: Multicomponent integrative intervention (cognitive training, dietary instruction, physical activity, management of vascular risk factors)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multicomponent integrative intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study: 33808526

Group type: EXPERIMENTAL
Intervention: Tai-Chi training (TC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Health education sessions (HE)
Number of subjects: 80
Study: 32107012

Group type: EXPERIMENTAL
Intervention: VR + CL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: VR
Number of subjects: 11
Study: 36002178

Group type: EXPERIMENTAL
Intervention: Listening to music (Sonata for Two Pianos in D Major, K.448)
Number of subjects: 121

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 121
Study: 34479673

Group type: EXPERIMENTAL
Intervention: PRF + OFD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 90

Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 90
Study: 33851329

Group type: EXPERIMENTAL
Intervention: 10 mg/kg Cr(VI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 30 mg/kg Cr(VI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 50 mg/kg Cr(VI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (0 mg/kg Cr(VI))
Number of subjects: 32
Study: 33992542

Group type: EXPERIMENTAL
Intervention: 3 months of oxaliplatin-based chemotherapy
Number of subjects: 6065

Group type: COMPARATOR
Intervention: 6 months of oxaliplatin-based chemotherapy
Number of subjects: 6065
Study: 35871058

Group type: EXPERIMENTAL
Intervention: MND-2119 2 g/day
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: MND-2119 4 g/day
Number of subjects: 580

Group type: COMPARATOR
Intervention: EPA-E 1.8 g/day
Number of subjects: 580

Group type: COMPARATOR
Intervention: EPA-E 2.7 g/day
Number of subjects: 580
Study: 33298604

Group type: EXPERIMENTAL
Intervention: Propofol Target-Controlled Infusion (TCI)
Number of subjects: 25
Study: 35978074

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (5% NaF) with professional cleaning every 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ozone therapy before varnishing (Groups II and IV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Octenidine mouthrinse (Groups III and IV)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (Group K) with no professional hygienic or prophylactic procedures
Number of subjects: 150
Study: 33130104

Group type: EXPERIMENTAL
Intervention: 3 g gluten/d for 14 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 g gluten/d for 14 days
Number of subjects: 14
Study: 32719231

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: KTP laser
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 209
Study: 35115180

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295